| 1 |
Leonardi GC, Falzone L, Salemi R, et al. Cutaneous melanoma: From pathogenesis to therapy (Review) [J]. Int J Oncol, 2018, 52(4): 1071-1080.
|
| 2 |
Boone B, Jacobs K, Ferdinande L, et al. EGFR in melanoma: clinical significance and potential therapeutic target [J]. J Cutan Pathol, 2011, 38(6): 492-502.
|
| 3 |
Karimkhani C, Green AC, Nijsten T, et al. The global burden of melanoma: results from the Global Burden of Disease Study 2015 [J]. Brit J Dermatol, 2017, 177(1): 134-140.
|
| 4 |
Gross A, Niemetz-Rahn A, Nonnenmacher A, et al. Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway [J]. Target Oncol, 2015, 10(1): 77-84.
|
| 5 |
Hartman RI, Lin JY. Cutaneous melanoma-a review in detection, staging, and management [J]. Hematol Oncol Clin North Am, 2019, 33(1): 25-38.
|
| 6 |
丁娅, 郭轶群, 李婧婧, 等. 白蛋白结合型紫杉醇联合铂类治疗中国晚期黑色素瘤患者的疗效与安全性评价 [J]. 中山大学学报(医学科学版), 2015, 36(5): 683-688.
|
| 7 |
Ben-Hamo R, Zilberberg A, Cohen H, et al. Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types [J]. NPJ Precis Onc, 2019, 3(1): 12.
|
| 8 |
Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis [J]. Eur J Cancer, 2001, 37 Suppl 4: S9-15.
|
| 9 |
王雯竹, 何艳艳, 徐浩翔. EGFR通路在相关皮肤病发病机制中的研究进展 [J]. 中国麻风皮肤病杂志, 2020, 36(11): 697-700.
|
| 10 |
Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy [J]. Nature, 2007, 445(7130): 851-857.
|
| 11 |
Pópulo H, Soares P, Lopes J M. Insights into melanoma: targeting the mTOR pathway for therapeutics [J]. Expert Opin Ther Targets, 2012, 16(7): 689-705.
|
| 12 |
Domingues B, Lopes JM, Soares P, et al. Melanoma treatment in review [J]. Immunotargets Ther, 2018, 7: 35-49.
|
| 13 |
Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma [J]. New Engl J Med, 2004, 351(10): 998-1012.
|
| 14 |
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019 [J]. CA Cancer J Clin, 2019, 69 (5): 363-385.
|
| 15 |
Wada-Ohno M, Ito T, Furue M. Adjuvant therapy for melanoma[J]. Curr Treat Options Oncol, 2019, 20(8): 63.
|
| 16 |
Batus M, Waheed S, Ruby C, et al. Optimal management of metastatic melanoma: current strategies and future directions [J]. Am J Clin Dermatol, 2013, 14(3): 179-194.
|
| 17 |
Li J, Wang Y, Liang R, et al. Recent advances in targeted nanoparticles drug delivery to melanoma [J]. Nanomedicine, 2015, 11(3): 769-794.
|
| 18 |
Widakowich C, de Castro G, de Azambuja E, et al. Review: side effects of approved molecular targeted therapies in solid cancers [J]. Oncologist, 2007, 12(12): 1443-1455.
|
| 19 |
Austin E, Mamalis A, Ho D, et al. Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: a systematic review [J]. Arch Dermatol Res, 2017, 309(4): 229-242.
|
| 20 |
Desai N, Trieu V, Damascelli B, et al. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients [J]. Transl Oncol, 2009, 2(2): 59-64.
|
| 21 |
Weaver BA. How Taxol/paclitaxel kills cancer cells [J]. Mol Biol Cell, 2014, 25(18): 2677-2681.
|
| 22 |
Chen X, Wang M, Hu Y, et al. Low-dose paclitaxel via hyaluronan-functionalized bovine serum albumin nanoparticulate assembly for metastatic melanoma treatment [J]. J Mater Chem B, 2020, 8(10): 2139-2147.
|
| 23 |
贾东东, 李涛. 重组人血管内皮抑制素联合卡铂和紫杉醇对A375黑色素瘤细胞增殖及凋亡影响 [J]. 中华肿瘤防治杂志, 2019, 26(20): 1510-1514.
|
| 24 |
Morgillo F, Della Corte CM, Fasano M, et al. Mechanisms of resistance to EGFR-targeted drugs: lung cancer [J]. ESMO Open, 2016, 1(3): e000060.
|